DHMEQ has a unique specificity in blocking NF-κB activity [15], and preclinical studies on cancer cell lines or in xenograft settings have shown effective growth inhibition in several tumors, such as breast cancer [27], prostate cancer [28], bladder cancer [29], thyroid cancer [30], pancreatic cancer [31], head and neck carcinoma [32], multiple myeloma [33] and adult T-cell leukemia [34]. This evidence concerns the gene NFKB1 and breast cancer.